Literature DB >> 7840596

Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus.

X He1, R N Tiballi, L T Zarins, S F Bradley, J A Sangeorzan, C A Kauffman.   

Abstract

For 212 oropharyngeal isolates of Candida albicans, the fluconazole MICs for 50 and 90% of strains tested were 0.5 and 16 micrograms/ml, respectively, and those of itraconazole were 0.05 and 0.2 micrograms/ml, respectively. Of 16 isolates for which fluconazole MICs were > 64 micrograms/ml, itraconazole MICs for 14 were < or = 0.8 micrograms/ml and for 2 were > 6.4 micrograms/ml. Most fluconazole-resistant strains remained susceptible to itraconazole; whether itraconazole will prove effective for refractory thrush remains to be shown.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7840596      PMCID: PMC284772          DOI: 10.1128/AAC.38.10.2495

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests.

Authors:  A Espinel-Ingroff; C W Kish; T M Kerkering; R A Fromtling; K Bartizal; J N Galgiani; K Villareal; M A Pfaller; T Gerarden; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

2.  Candida albicans resistance in AIDS.

Authors:  V S Kitchen; M Savage; J R Harris
Journal:  J Infect       Date:  1991-03       Impact factor: 6.072

3.  Fluconazole resistant candida in AIDS.

Authors:  R Fox; K R Neal; C L Leen; M E Ellis; B K Mandal
Journal:  J Infect       Date:  1991-03       Impact factor: 6.072

4.  Itraconazole versus ketaconazole in the treatment of oral and oesophageal candidosis in patients infected with HIV.

Authors:  D E Smith; J Midgley; M Allan; G M Connolly; B G Gazzard
Journal:  AIDS       Date:  1991-11       Impact factor: 4.177

5.  Modification of gastric pH with oral glutamic acid hydrochloride.

Authors:  M J Knapp; R R Berardi; J B Dressman; J M Rider; P L Carver
Journal:  Clin Pharm       Date:  1991-11

6.  Association of gastric hypoacidity with opportunistic enteric infections in patients with AIDS.

Authors:  P C Belitsos; J K Greenson; J H Yardley; J R Sisler; J G Bartlett
Journal:  J Infect Dis       Date:  1992-08       Impact factor: 5.226

7.  The pharmacokinetics of oral itraconazole in AIDS patients.

Authors:  D Smith; V van de Velde; R Woestenborghs; B G Gazzard
Journal:  J Pharm Pharmacol       Date:  1992-07       Impact factor: 3.765

8.  Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS).

Authors:  G Lake-Bakaar; W Tom; D Lake-Bakaar; N Gupta; S Beidas; M Elsakr; E Straus
Journal:  Ann Intern Med       Date:  1988-09-15       Impact factor: 25.391

9.  Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype.

Authors:  L Millon; A Manteaux; G Reboux; C Drobacheff; M Monod; T Barale; Y Michel-Briand
Journal:  J Clin Microbiol       Date:  1994-04       Impact factor: 5.948

10.  The prevalence of oral lesions in HIV-infected homosexual and bisexual men: three San Francisco epidemiological cohorts.

Authors:  D W Feigal; M H Katz; D Greenspan; J Westenhouse; W Winkelstein; W Lang; M Samuel; S P Buchbinder; N A Hessol; A R Lifson
Journal:  AIDS       Date:  1991-05       Impact factor: 4.177

View more
  14 in total

Review 1.  Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome.

Authors:  M A Ghannoum; J H Rex; J N Galgiani
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

2.  Reversible fluconazole resistance in Candida albicans: a potential in vitro model.

Authors:  H M Calvet; M R Yeaman; S G Filler
Journal:  Antimicrob Agents Chemother       Date:  1997-03       Impact factor: 5.191

3.  Variation in fluconazole efficacy for Candida albicans strains sequentially isolated from oral cavities of patients with AIDS in an experimental murine candidiasis model.

Authors:  F Barchiesi; L K Najvar; M F Luther; G Scalise; M G Rinaldi; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

Review 4.  Azole resistance in Candida.

Authors:  D W Denning; G G Baily; S V Hood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-04       Impact factor: 3.267

5.  Selection of Candida glabrata strains with reduced susceptibility to azoles in four liver transplant patients with invasive candidiasis.

Authors:  J Fortún; A López-San Román; J J Velasco; A Sánchez-Sousa; E de Vicente; J Nuño; C Quereda; R Bárcena; G Monge; A Candela; A Honrubia; A Guerrero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-04       Impact factor: 3.267

6.  Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis.

Authors:  K Hata; J Kimura; H Miki; T Toyosawa; M Moriyama; K Katsu
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

7.  Comparison of three methods for testing azole susceptibilities of Candida albicans strains isolated sequentially from oral cavities of AIDS patients.

Authors:  A M Tortorano; M A Viviani; F Barchiesi; D Arzeni; A L Rigoni; M Cogliati; P Compagnucci; G Scalise
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

Review 8.  Fungal infections: a growing threat.

Authors:  D M Dixon; M M McNeil; M L Cohen; B G Gellin; J R La Montagne
Journal:  Public Health Rep       Date:  1996 May-Jun       Impact factor: 2.792

Review 9.  Current and emerging azole antifungal agents.

Authors:  D J Sheehan; C A Hitchcock; C M Sibley
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

Review 10.  Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches.

Authors:  B D Alexander; J R Perfect
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.